US Patent 6949245 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
Patent 6949245 was granted and assigned to Genentech on September, 2005 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 9 Oct, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 29 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 27 Oct, 2023
Golden AI
Edits made to:
Infobox (+10 properties)
Article (+181 characters)
Article
Patent abstract
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
Infobox
Is a
Patent Applicant
0
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Mark Sliwkowski0
Date of Patent
September 27, 2005
0Patent Application Number
096028120
Date Filed
June 23, 2000
0Patent Primary Examiner
Golden AI
Edits made to:
US Patent 6949245 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
Find more entities like US Patent 6949245 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.